Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Medicover: Year-end report January-December 2023


News provided by

Medicover

09 Feb, 2024, 07:16 GMT

Share this article

Share toX

Share this article

Share toX

STOCKHOLM, Feb. 9, 2024 /PRNewswire/ --

Fourth quarter

  • Revenue amounted to €461.9m (€397.7m), an increase of 16.1% with an organic growth of 13.5%.
  • Operating profit (EBIT) was €19.0m (€8.9m), an increase of 117.2%, representing an operating margin of 4.1% (2.2%).
  • Net profit amounted to €8.6m (€2.3m), which represents a margin of 1.9% (0.6%).
  • EBITDA was €66.4m (€53.2m), an increase of 25.3%. EBITDA margin was 14.4% (13.3%).
  • EBITDAaL amounted to €40.8m (€30.1m), an increase by 36.1%, corresponding to an EBITDAaL margin of 8.8% (7.5%).
  • Net cash flow from operating activities was €42.5m (€41.2m).
  • Basic/diluted earnings per share were €0.078 (€0.013). 
                 

Full year

  • Revenue amounted to €1,746.4m (€1,510.2m), an increase of 15.6% with an organic growth of 11.6%.
  • Operating profit (EBIT) was €61.4m (€55.2m), representing an operating margin of 3.5% (3.7%).
  • Net profit amounted to €18.4m (€13.7m), which represents a margin of 1.1% (0.9%).
  • EBITDA was €243.8m (€217.1m), an increase by 12.3%. EBITDA margin was 14.0% (14.4%).
  • EBITDAaL amounted to €144.9m (€130.9m), corresponding to an EBITDAaL margin of 8.3% (8.7%).
  • Net cash flow from operating activities was €205.0m (€170.2m).
  • Basic/diluted earnings per share were €0.118 (€0.079).
  • The board of directors proposes a dividend for 2023 of €0.12 (€0.12) per share.

REVENUE AND EARNINGS

€ millions (€m)

Q4
                                                2023

Q4
                                                20221)

Variance

FY
                                                2023

FY
                                                20221)

Variance

Revenue

461.9

397.7

16 %

1,746.4

1,510.2

16 %

Operating profit (EBIT)

19.0

8.9

117 %

61.4

55.2

11 %

Operating profit margin

4.1 %

2.2 %


3.5 %

3.7 %


Net profit

8.6

2.3

289 %

18.4

13.7

35 %

Net profit margin

1.9 %

0.6 %


1.1 %

0.9 %


Basic/diluted earnings per share, €

0.078

0.013

500 %

0.118

0.079

49 %

EBITDA

66.4

53.2

25 %

243.8

217.1

12 %

EBITDA margin

14.4 %

13.3 %


14.0 %

14.4 %


Adjusted EBITDA

68.3

57.9

18 %

253.9

233.9

9 %

Adjusted EBITDA margin

14.8 %

14.5 %


14.5 %

15.5 %


EBITDAaL

40.8

30.1

36 %

144.9

130.9

11 %

EBITDAaL margin

8.8 %

7.5 %


8.3 %

8.7 %


Adjusted EBITDAaL

42.7

34.8

23 %

155.0

147.7

5 %

Adjusted EBITDAaL margin

9.2 %

8.7 %


8.9 %

9.8 %


EBITA

23.3

15.4

53 %

82.6

80.9

2 %

EBITA margin

5.1 %

3.8 %


4.7 %

5.4 %


Definition and reconciliation of alternative performance measures are available at www.medicover.com/financial-information.
1) 2022 is restated for IFRS 17 Insurance contracts. For further information, refer to note 1.

CEO Statement

I am pleased to look back at another year of strong growth. In February 2023, we announced new, even more ambitious growth targets for the next three-year period, and so far, we have delivered on our plan to meet the new targets. This is a clear message in a still very challenging world.

If we look further back to 2019, the last undisturbed year, before Covid-19 and the war in Ukraine, we have more than doubled revenue and EBITDA during these four years, while we also have invested more growth capital for future growth than ever before. A very strong achievement of which we are very proud. The last four years have arguably been the most challenging times in Europe for many decades. This performance is a strong testament to the diversification of our business model and the essential services offered, as well as the underlying growth of our markets.

After a couple of years of significant investments, last year we have worked on consolidating acquired businesses, improved operational efficiency, and increased capacity utilisation. We have continued our organic growth capital investments in line with historic levels, while we have significantly slowed down acquisition growth, as communicated beginning of last year. During the last two quarters of the year, we have seen an increase in our main profit measures compared to the same quarters in previous year. However, margins in Diagnostic Services remain under pressure as we have not yet seen an increase of the reimbursement levels in Germany. In Healthcare Services we are negatively impacted by new hospital start-ups in India and Romania. Despite this, EBITDA in the quarter increased by over 25% for the Group.

Unfortunately, the war in Ukraine shows no signs of abating. Our colleagues there are doing a phenomenal job. Ukraine represents 4 per cent of total business and we are back around pre-war volume levels, a testament to the resilience and adaptability of our operations in the face of challenging circumstances.

Revenue for the quarter continued to grow strongly and was up 16.1% to €461.9m (€397.7m), with an organic growth of 13.5%. Revenue for the year grew 15.6% to €1,746.4m (€1,510.2m) with an organic growth of 11.6%.

EBITDA in the quarter was €66.4m (€53.2m), an increase by 25.3%, representing an EBITDA margin of 14.4% (13.3%). EBITDA for the full year amounted to €243.8m (€217.1m), a margin of 14.0% (14.4%).

Fee-For-Service and other services (FFS) increased by 11.9% in the quarter, now representing 57% of total revenue. Full year FFS revenue growth was 13.8%, representing 58% of total revenue.

Healthcare Services quarterly revenue grew by 25.2% to €324.4m (€259.0m), with an organic growth of 19.1%. Revenue growth in the year was 30.6%, with an organic growth of 21.0%, reaching €1,197.7m (€917.1m).

At the end of the year the division had 1.8 million members, growing with 34 thousand members over the quarter and with 103 thousand members for the year. We continue to see very robust trading in our corporate paid business, particularly in Poland in both Health and Sport, but also in Romania.

FFS increased by 19.7% in the quarter and represented 53% of divisional revenue, full year FFS revenue growth was 28.5%.

EBITDA grew by 20.8% in the quarter to €46.2m (€38.4m), an EBITDA margin of 14.3% (14.8%). EBITDA for the year grew by 36.8% to €171.8m (€125.6m), an EBITDA margin of 14.3% (13.7%).

Diagnostic Services revenue amounted to €143.1m (€143.9m), a decrease by 0.6%, with an organic growth of 3.2%. Excluding Covid revenue in the comparative quarter, organic growth was a healthy 11.5%, illustrating the positive underlying volume development. Revenue growth for the year was -6.7%, with an organic reduction of 2.5%, amounting to €571.2m (€612.5m).

29.3 million tests were performed in the quarter (29.3 million) and 119.2 million tests in the full year (119.3 million). FFS increased by 0.2% in the quarter, now representing 68% of divisional revenue, full year FFS revenue decrease was 4.4%.

EBITDA amounted to €20.4m (€23.0m), a decrease of 10.7%, an EBITDA margin of 14.3% (15.9%). EBITDA in the full year amounted to €88.1m (€118.7m), a decrease of 25.7% and mainly related to no contribution from Covid-19, an EBITDA margin of 15.4% (19.4%).

As we navigate the landscape of 2024, we find ourselves in a robust position, with investments from previous years that will continue to mature supported by continued growth investments. As the year progresses, we are also likely to be more active with our acquisition agenda. 

We remain confident on the trading outlook for 2024, with continued good organic growth and continued profit improvement, this puts us on a good path to be able to achieve the medium-term financial targets for the period 2023-2025.

Financial targets by year-end 2025:

  • organic revenue should exceed €2.2bn
  • An adjusted organic EBITDA in excess of €350m
  • Loans payable net of cash and liquid short-term investments/adjusted EBITDAaL ≤3.5x

I would like to express a sincere gratitude to all our staff across our markets for their dedication, hard-work, and professionalism – thank you.

Fredrik Rågmark
CEO 

This report has not been subject to review by the Company's auditor.
For full report, see attached pdf.

This is information that Medicover AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication through the agency of the contact person set out below at 7.45 (CET) on 9 February 2024. This year-end report and other information about Medicover is available at medicover.com.

Financial calendar
Annual report                                                                                               week 13 2024
Interim report January-March                                                                      26 April 2024, 7.45 CEST
Annual general meeting                                                                               26 April 2024
Interim report April-June                                                                              25 July 2024, 7.45 CEST
Interim report July-September                                                                    30 October 2024, 7.45 CET

For further information, please contact:
Hanna Bjellquist, Head of Investor Relations
Phone: +46 70 303 32 72
E-mail: hanna.bjellquist@medicover.com

Conference call: A conference call for analysts and investors will be held today at 09.30 CET. To listen in please register here. To ask questions please register here.

Medicover is a leading international healthcare and diagnostic services company and was founded in 1995. Medicover operates a large number of ambulatory clinics, hospitals, specialty-care facilities, laboratories and blood-drawing points and the largest markets are Poland, Germany, Romania and India. In 2023, Medicover had revenue of €1,746 million and more than 45,000 employees. For more information, go to www.medicover.com

The following files are available for download:

https://mb.cision.com/Main/15662/3925472/2593407.pdf

Year-end report 2023

Modal title

Also from this source

Medicover: Year-end report January-December 2024

Fourth quarter Revenue amounted to €555.8m (€461.9m), an increase of 20.3% with an organic growth of 18.6%. Operating profit (EBIT) was €23.3m...

John Stubbington appointed new CEO of Medicover from 1 May 2025

The Board of Directors of Medicover AB (publ) ("Medicover") today announces that John Stubbington will succeed Fredrik Rågmark as new CEO of the...

More Releases From This Source

Explore

Medical Pharmaceuticals

Medical Pharmaceuticals

Health Care & Hospitals

Health Care & Hospitals

Earnings

Earnings

Earnings

Earnings

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.